top of page

35+ YEARS IN MEDICAL DEVICE | PHARMACEUTICAL | BIOTECHNOLOGY | DIAGNOSTICS

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

Search

Travere Therapeutics Names Bradley Campbell as New CEO in Planned Leadership Transition

2 days ago

1 min read

San Diego, CA, September 21, 2026 (Business Wire) -- Travere Therapeutics announced that Eric Dube, Ph.D., will step down as President and CEO in December after nearly eight years leading the company. Bradley L. Campbell, former President and CEO of Amicus Therapeutics, will succeed Dube effective December 1, 2026, and will also join Travere’s Board of Directors. Dube will remain with the company as an executive advisor through February 15, 2027, to support the leadership transition.

Read full article here.

Recent Posts

Anaconda Biomed Raises $56M to Advance Stroke Thrombectomy Platform

Barcelona, Spain and Marin, CA, September 23, 2026 (Globe Newswire) -- Anaconda Biomed has closed a $56 million financing round led by Omega Funds, with participation from new investor Spain’s Co-in

Axogen to Acquire BioCircuit Technologies for $200M to Expand Peripheral Nerve Repair Portfolio

Alachua and Tampa, FL, September 10, 2026 (Axogen) -- Axogen has entered into a definitive agreement to acquire privately held medical device company BioCircuit Technologies for $200 million in cash

CereVasc Appoints Tony Kingsley as CEO Ahead of eShunt Commercial Launch

Boston, MA, September 15, 2026 (PR Newswire) -- CereVasc has appointed Tony Kingsley as President and Chief Executive Officer, effective September 15, succeeding Dan Levangie, who will transition to

Comments

Life Science Headlines

Anaconda Biomed Raises $56M to Advance Stroke Thrombectomy Platform

Travere Therapeutics Names Bradley Campbell as New CEO in Planned Leadership Transition

Axogen to Acquire BioCircuit Technologies for $200M to Expand Peripheral Nerve Repair Portfolio

CereVasc Appoints Tony Kingsley as CEO Ahead of eShunt Commercial Launch

Electra Therapeutics Prices Upsized $350M IPO to Fund Late-Stage Drug Development

Superluminal Medicines Secures $60M Series B to Advance Rare Obesity Drug Into Clinical Trials

Oligomerix Names Cara Cassino as Interim CEO to Lead Next Stage of Alzheimer’s Drug Development

NeuShen Therapeutics Raises More Than $80M in Series B to Accelerate Global CNS Drug Development

Vivace Therapeutics Appoints New CEO as VT3989 Moves Toward Phase 3 Mesothelioma Trial

Elucid Raises $55M Series D to Expand AI-Powered Cardiovascular Imaging Platform

bottom of page